within Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CX06_DipiperonylaminoethanolC;

model DipiperonylaminoethanolC
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.5,
    Cl = 3.333333333333333e-07,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.04,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0005,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>DipiperonylaminoethanolCombinations</td></tr><tr><td>ATC code:</td><td>N05CX06</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>40</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dipiperonylaminoethanol is a piperidine derivative previously used as a sedative and tranquilizer. It was generally applied for its central nervous system depressant and anxiolytic properties. The drug is not widely approved or in current use today and has largely fallen out of medical practice.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult individuals due to absence of published PK data for dipiperonylaminoethanol combinations.</p><h4>References</h4><ol><li><p>Zamir, A, et al., &amp; Rasool, MF (2022). Clinical Pharmacokinetics of Metoprolol: A Systematic Review. <i>Clinical pharmacokinetics</i> 61(8) 1095–1114. DOI:<a href=\"https://doi.org/10.1007/s40262-022-01145-y\">10.1007/s40262-022-01145-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35764772/\">https://pubmed.ncbi.nlm.nih.gov/35764772</a></p></li><li><p>Keizer, RJ, et al., &amp; Beijnen, JH (2010). Clinical pharmacokinetics of therapeutic monoclonal antibodies. <i>Clinical pharmacokinetics</i> 49(8) 493–507. DOI:<a href=\"https://doi.org/10.2165/11531280-000000000-00000\">10.2165/11531280-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20608753/\">https://pubmed.ncbi.nlm.nih.gov/20608753</a></p></li><li><p>Echizen, H (2016). The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. <i>Clinical pharmacokinetics</i> 55(4) 409–418. DOI:<a href=\"https://doi.org/10.1007/s40262-015-0326-7\">10.1007/s40262-015-0326-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26369775/\">https://pubmed.ncbi.nlm.nih.gov/26369775</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05CX06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end DipiperonylaminoethanolC;
